Teva Honored With Power of Partnership Award for Global Health Impact
The award was presented to Carol Richardson, Teva's U.S. Head of Sustainability and Health Equity, during the HDA Business and Leadership Conference in Orlando, Florida, on June 2.
A Legacy of Giving
Teva's partnership with Americares spans nearly three decades, during which the company has donated enough medicine to fill nearly 19 million prescriptions. In 2024 alone, Teva contributed $48 million worth of essential medicines to Americares to support health centers in low- and middle-income countries.
These donations have reached 124 countries, providing treatments for respiratory illnesses, hypertension, diabetes, depression, and more. Teva's support has also been critical in disaster response efforts, including the 2010 Haiti earthquake, flooding in the Philippines, and the ongoing humanitarian crisis in Ukraine.
'Expanding access to medicines for underserved populations is a core element of Teva's Healthy Future sustainability strategy,' said Richardson. 'Teva is honored to receive this prestigious recognition from Americares, our longstanding partner, and we look forward to continuing our work together to help provide quality care to people in need around the world.'
Innovation in Access
In 2024, Teva launched a produce-to-give program, creating a dedicated supply of essential medicines for three Americares partner health facilities in El Salvador. In its first year, the program delivered enough medicine to fill over 13,500 prescriptions, addressing infections, cardiovascular disease, and gastrointestinal conditions.
Recognizing Impact
'Teva is one of Americares most dedicated and longstanding supporters,' said Dr. Adam Schwartz, Deputy Medical Officer at Americares. 'With Teva's support, we are increasing access to health for people and communities in need all over the world.'
HDA President and CEO Chester 'Chip' Davis, Jr. added, 'We applaud Teva's work with Americares to donate lifesaving medicines to patients worldwide, as well as Teva's commitment to enhancing health outcomes for individuals.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
"It was kind of challenging but it was all for the good" - Luka Doncic reveals he gave up basketball to improve his conditioning for the next season
"It was kind of challenging but it was all for the good" - Luka Doncic reveals he gave up basketball to improve his conditioning for the next season originally appeared on Basketball Network. By now, the whole world has seen the transformation that Luka Doncic has made in his body in his first offseason as a Los Angeles Laker. This has not only surprised the consensus but also instilled belief that the 26-year-old superstar might just put together his best basketball season in his remarkable career so far. But ironically, what also led to Doncic's weight loss this summer wasn't basketball. In fact, the Slovenian sensation revealed that he had to be forced to stay away from it and take a whole new approach this offseason in order to achieve his goals. "I would say me and my team just tried different new things. Different food, different practices," he said. "I actually gave up playing basketball for one month, which I've never done in my life. So it was kind of challenging, but it was all good," said Doncic in his appearance on The Today's Show. Out with the old, in with the new While losing what seems to be more than 10 pounds, the 6'7" guard pursued playing other sports religiously, such as pickleball and padel. Doncic said that it helped that he played multiple sports as a kid growing up, which was why he eventually made peace with the fact that he wouldn't play basketball for a month. Instead of playing basketball, the international superstar focused on getting his diet right and placing more emphasis on weight training. Without playing basketball for the first time in years, the five-time All-Star also let his body recover completely, especially after a season that saw him miss 32 regular-season games because of a severe calf injury. This offseason, Doncic made it a point to lose weight, build muscle strength, and get right mentally. "This year, with my team, I think we did a huge step. But this is just the start, you know. I need to keep going. Can't stop," Doncic told Men's Health Magazine earlier this week. In prime position to bounce back Doncic also said he didn't lose weight to prove a point against his many critics who have long called him out for being out of shape. Instead, he did it for himself because he knows he needs to take advantage of his prime years while they're still around. It also helps that he's never been doubted the way he was last season, when not only the Dallas Mavericks traded him to the Lakers, but his early playoff exit led him to be more motivated than ever to come back stronger. "Honestly, I tried to not read much. Just tried to focus," he said about his critics. "I think I was still a pretty good basketball player back then, no matter what people say." True enough, an "out-of-shape" Doncic has averaged 28.6 points, 8.6 rebounds, and 8.2 assists thus far in his seven-year stint in the NBA. If he was able to be a top five player over the last couple of years, what more now with his change in approach in regards to his fitness? Time will eventually tell how monumental this summer would eventually end up impacting The Don's career moving story was originally reported by Basketball Network on Jul 31, 2025, where it first appeared.
Yahoo
an hour ago
- Yahoo
Why Novo Nordisk Stock Bumped Higher on Friday
Key Points The Federal government might boost its support of weight-loss drugs soon. According to a media report, it's contemplating a five-year, experimental program that would subsidize their costs for qualifying patients. 10 stocks we like better than Novo Nordisk › Unexpected news of a potential support program from the federal government boosted the share prices of weight-loss drug developers on Friday. The poster boy for that still rather small group, Wegovy/Ozempic maker Novo Nordisk (NYSE: NVO), understandably saw a stock price lift that day. It rose by more than 2%, contrasting well with the 1.6% slide of the S&P 500 index. Federal help for obesity drugs? That news came from The Washington Post, which published an article stating that the Trump administration is planning an experimental program that would cover the costs of such medications. Citing documents from the Centers for Medicare and Medicaid Services (CMS) it had obtained, the newspaper said the plan would be implemented by state Medicaid administrations. It would also be utilized by Medicare Part D insurance plans. These entities would be allowed to cover weight-loss drugs for qualifying patients. At the moment, Medicare generally covers such treatments for patients who suffer from type 2 diabetes. Both Novo Nordisk's Wegovy and rival Eli Lilly's Zepbound are essentially versions of predecessor diabetes drugs. Some private insurance plans cover obesity medications. The Post wrote that the experimental program will last for five years. Massive potential impact Novo Nordisk hasn't yet commented on the article, but we can be sure the company is excited about the prospect. Combined, Medicare and Medicaid are immense programs. Even if only a few states are willing to cover weight-loss treatments through them, the company could experience a surge in sales. For the stock's investors, this is a potentially very impactful development well worth monitoring. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Stock Bumped Higher on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Addus HomeCare (ADUS) Q2 Earnings: What To Expect
Home healthcare provider Addus HomeCare (NASDAQ:ADUS) will be reporting results this Monday afternoon. Here's what you need to know. Addus HomeCare missed analysts' revenue expectations by 0.6% last quarter, reporting revenues of $337.7 million, up 20.3% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' sales volume estimates. Is Addus HomeCare a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Addus HomeCare's revenue to grow 20.8% year on year to $346.5 million, improving from the 10.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.46 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Addus HomeCare has missed Wall Street's revenue estimates three times over the last two years. Looking at Addus HomeCare's peers in the senior health, home health & hospice segment, some have already reported their Q2 results, giving us a hint as to what we can expect. BrightSpring Health Services delivered year-on-year revenue growth of 15.3%, beating analysts' expectations by 5.2%, and Option Care Health reported revenues up 15.4%, topping estimates by 4.6%. Option Care Health traded down 2.7% following the results. Read our full analysis of BrightSpring Health Services's results here and Option Care Health's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the senior health, home health & hospice stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Addus HomeCare is down 5.3% during the same time and is heading into earnings with an average analyst price target of $136.45 (compared to the current share price of $104.74). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
